ATE202487T1 - Mono- oder polyfunktionelle konjugate von polylysine - Google Patents
Mono- oder polyfunktionelle konjugate von polylysineInfo
- Publication number
- ATE202487T1 ATE202487T1 AT95940329T AT95940329T ATE202487T1 AT E202487 T1 ATE202487 T1 AT E202487T1 AT 95940329 T AT95940329 T AT 95940329T AT 95940329 T AT95940329 T AT 95940329T AT E202487 T1 ATE202487 T1 AT E202487T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- polylysine
- diseases
- mono
- sec
- Prior art date
Links
- 108010039918 Polylysine Proteins 0.000 title abstract 3
- 229920000656 polylysine Polymers 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 3
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 206010067722 Toxic neuropathy Diseases 0.000 abstract 1
- 231100000126 Toxic neuropathy Toxicity 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Polyamides (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9413861A FR2727117A1 (fr) | 1994-11-18 | 1994-11-18 | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| PCT/FR1995/001517 WO1996015810A1 (fr) | 1994-11-18 | 1995-11-17 | Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE202487T1 true ATE202487T1 (de) | 2001-07-15 |
Family
ID=9468953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95940329T ATE202487T1 (de) | 1994-11-18 | 1995-11-17 | Mono- oder polyfunktionelle konjugate von polylysine |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6114388A (https=) |
| EP (1) | EP0792167B1 (https=) |
| JP (1) | JP4128618B2 (https=) |
| AT (1) | ATE202487T1 (https=) |
| AU (1) | AU694825B2 (https=) |
| CA (1) | CA2205557C (https=) |
| DE (1) | DE69521521T2 (https=) |
| DK (1) | DK0792167T3 (https=) |
| ES (1) | ES2161915T3 (https=) |
| FR (1) | FR2727117A1 (https=) |
| GR (1) | GR3036710T3 (https=) |
| NZ (1) | NZ297040A (https=) |
| PT (1) | PT792167E (https=) |
| WO (1) | WO1996015810A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO104396A0 (en) * | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Antiviral linear polymers |
| CA2284729A1 (en) | 1997-04-18 | 1998-10-29 | Novartis Ag | Neoglycoproteins |
| FR2763853B1 (fr) * | 1997-05-28 | 2000-01-07 | Oreal | Association d'un retinoide avec un polymere polyamine |
| DE19732139C2 (de) | 1997-07-25 | 2002-10-10 | Max Planck Gesellschaft | Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| FR2773808B1 (fr) * | 1998-01-20 | 2000-05-05 | Sagebo | Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation |
| US6919076B1 (en) * | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| US6686446B2 (en) * | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| GB9811059D0 (en) * | 1998-05-23 | 1998-07-22 | Univ Strathclyde | Polyamino acid vesicles |
| ES2235499T3 (es) | 1998-07-30 | 2005-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. |
| CA2372526A1 (en) * | 1999-05-10 | 2000-11-16 | Michael D. Wyrsta | Methods and compositions for controlled polypeptide synthesis |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| FR2842422B1 (fr) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
| RU2327487C2 (ru) * | 2002-08-08 | 2008-06-27 | Бейлор Колледж Оф Медисин | Выделение и идентификация т-клеток |
| DE60321363D1 (de) * | 2002-08-28 | 2008-07-10 | Millipore Corp | Verfahren zur aufreinigung von sequenzierungsreaktionen |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| US7473687B2 (en) * | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| US20090325920A1 (en) | 2005-03-24 | 2009-12-31 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| FR2886153B1 (fr) * | 2005-05-27 | 2009-04-10 | Gemac Sa | Composition destinee au traitement de la sclerose en plaques |
| CA2651328A1 (en) * | 2006-05-05 | 2007-11-15 | Opexa Therapeutics | T-cell vaccine |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| CN101622017B (zh) | 2006-12-22 | 2018-09-11 | 克罗马制药有限责任公司 | 聚合物的用途 |
| FR2913335B1 (fr) | 2007-03-06 | 2009-06-05 | Michel Geffard | Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes. |
| EP2085082A1 (en) * | 2008-01-29 | 2009-08-05 | Nutromnia S.R.L. | Treatment of cognitive decline |
| EP2696868A1 (en) * | 2011-04-12 | 2014-02-19 | Nestec S.A. | Nutritional compositions including branched chain fatty acids and methods of using same |
| SI3116887T1 (sl) | 2014-03-13 | 2021-06-30 | Universitaet Basel | Ogljikohidratni ligandi, ki se vežejo na protitelesa img proti glikoproteinu, ki je povezan z mielinom |
| FR3030524B1 (fr) * | 2014-12-17 | 2017-01-20 | Hydro-Fill | Utilisation de pll pour ameliorer la stabilite de molecules en solution |
| US11091591B2 (en) | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| FR3048616B1 (fr) * | 2016-03-14 | 2018-04-06 | Polyneuros | Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique |
| FR3122573B1 (fr) * | 2021-05-10 | 2024-03-29 | Hydro Fill Tech | Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine |
| FR3122571B1 (fr) * | 2021-05-10 | 2023-05-12 | Hydro Fill Tech | Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55500053A (https=) * | 1978-01-16 | 1980-01-31 | ||
| DE3546150A1 (de) * | 1985-06-24 | 1987-01-22 | Hoechst Ag | Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung |
| GB9004538D0 (en) * | 1990-02-28 | 1990-04-25 | Offord Robin E | Chemical compounds |
| DK0575545T3 (da) * | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| WO1993025197A1 (en) * | 1992-06-12 | 1993-12-23 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| FR2705234B1 (fr) * | 1993-05-19 | 1995-08-04 | Geffard Michel | Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA. |
-
1994
- 1994-11-18 FR FR9413861A patent/FR2727117A1/fr active Granted
-
1995
- 1995-11-17 AT AT95940329T patent/ATE202487T1/de not_active IP Right Cessation
- 1995-11-17 DE DE69521521T patent/DE69521521T2/de not_active Expired - Lifetime
- 1995-11-17 PT PT95940329T patent/PT792167E/pt unknown
- 1995-11-17 AU AU41811/96A patent/AU694825B2/en not_active Ceased
- 1995-11-17 JP JP51662296A patent/JP4128618B2/ja not_active Expired - Fee Related
- 1995-11-17 CA CA002205557A patent/CA2205557C/en not_active Expired - Lifetime
- 1995-11-17 WO PCT/FR1995/001517 patent/WO1996015810A1/fr not_active Ceased
- 1995-11-17 DK DK95940329T patent/DK0792167T3/da active
- 1995-11-17 ES ES95940329T patent/ES2161915T3/es not_active Expired - Lifetime
- 1995-11-17 US US08/836,199 patent/US6114388A/en not_active Expired - Lifetime
- 1995-11-17 EP EP95940329A patent/EP0792167B1/fr not_active Expired - Lifetime
- 1995-11-17 NZ NZ297040A patent/NZ297040A/xx unknown
-
2001
- 2001-09-26 GR GR20010401567T patent/GR3036710T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2205557C (en) | 2008-07-15 |
| EP0792167B1 (fr) | 2001-06-27 |
| FR2727117B1 (https=) | 1997-02-21 |
| NZ297040A (en) | 1999-05-28 |
| PT792167E (pt) | 2001-12-28 |
| DK0792167T3 (da) | 2001-10-29 |
| WO1996015810A1 (fr) | 1996-05-30 |
| AU4181196A (en) | 1996-06-17 |
| US6114388A (en) | 2000-09-05 |
| AU694825B2 (en) | 1998-07-30 |
| FR2727117A1 (fr) | 1996-05-24 |
| DE69521521T2 (de) | 2002-04-25 |
| JPH10511643A (ja) | 1998-11-10 |
| CA2205557A1 (en) | 1996-05-30 |
| JP4128618B2 (ja) | 2008-07-30 |
| ES2161915T3 (es) | 2001-12-16 |
| DE69521521D1 (de) | 2001-08-02 |
| EP0792167A1 (fr) | 1997-09-03 |
| GR3036710T3 (en) | 2001-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE202487T1 (de) | Mono- oder polyfunktionelle konjugate von polylysine | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| MY132529A (en) | Paroxetine hydrochloride anhydrate | |
| AU2291097A (en) | Novel phenanthridines substituted in the 6 position | |
| ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| DE69333931D1 (de) | Verwendung von Krillenzymen zur Behandlung von Zahnbelag | |
| NO972391D0 (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
| EP0830456A4 (en) | INSULATED FrpB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE | |
| SI0989973T1 (sl) | Halkoni z antiproliferativno aktivnostjo | |
| DE59510667D1 (de) | Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien | |
| DE69120287D1 (en) | Aminosulfonylharnstoff-acat-inhibitoren | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| AU6415994A (en) | Substituted caprolactams and derivatives thereof useful for treatment of hiv disease | |
| ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
| ATE305052T1 (de) | Drogen untersuchungssystem | |
| DE69726602D1 (en) | Hepatitis b inhibitoren | |
| TR199800850T2 (xx) | Kan� d�zenleyici bile�imler. | |
| NZ505085A (en) | Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi | |
| FR2657882B1 (fr) | Fragments d'adn comprenant le gene de la 1-deshydrogenase, micro-organismes transformes par lesdits fragments et applications desdits fragments et micro-organismes. | |
| ATE247467T1 (de) | Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |